Letter to the Editor - Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer an exploratory, open-label phase II study.
APA
Sun M, Zang D, Chen J (2026). Letter to the Editor - Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer an exploratory, open-label phase II study.. International journal of surgery (London, England), 112(2), 5329-5330. https://doi.org/10.1097/JS9.0000000000003673
MLA
Sun M, et al.. "Letter to the Editor - Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer an exploratory, open-label phase II study.." International journal of surgery (London, England), vol. 112, no. 2, 2026, pp. 5329-5330.
PMID
41133409
같은 제1저자의 인용 많은 논문 (5)
- Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients.
- Prolonged survival with alectinib in a patient with advanced lung adenocarcinoma: a case report and literature review.
- Clarifying the survival impact of immunotherapy in HR+/HER2- metastatic breast cancer: methodological caveats from a real-world perspective - Letter to the Editor.
- Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study.
- Rethinking AI-based prediction of NAT response in breast cancer: toward mechanistic and subtype-aware modeling - Letter to the Editor.